| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism |
|
Medicine details |
|
| Medicine name | rivaroxaban (Xarelto®) |
| Formulation | film-coated tablet |
| Reference number | 1003 |
| Indication | Treatment of deep vein thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults |
| Company | Bayer Healthcare Pharmaceuticals |
| BNF chapter | Cardiovascular system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 25/11/2011 |
| NICE guidance | |